2015-03-11 17:32
（吉隆坡11日訊）發馬（PHARMA,7081,主板貿服組）子公司發馬物流與國大（UKM）簽供應合約，負責採購、儲藏、供應與傳輸國大藥物與非藥物；供應合約由3月10日起生效，至2019年11月30日止。
分析
豐隆研究對此發展看法正面，這將擴大發馬的市場和對公司盈利提供激勵。
豐隆認為，這也開啟更多契機，以讓發馬供應與傳輸藥物與更多醫藥大學，並與相關醫藥大學建立更久遠伙伴關係。
發馬剛於今年2月13日與理大（USM）簽相同供應合約。藥物總值將視批准產品的實質份量、單位價格而定。
發馬催化因素包括獲非特許經營與私人界的市佔、從併購獲益、外匯優勢與有效營運策略，至於風險包括政治、法規等限制。
豐隆維持發馬“買進”評級，目標價由6令吉調高至6令吉21仙。（星洲日報／財經）
點看全文: http://biz.sinchew.com.my/node/111695?tid=18#ixzz3U8k43DWd
| Chart | Stock Name | Last | Change | Volume |
|---|
1
2
Koon Yew Yin's Blog
CPO price is rising rapidly as shown by chart below - Koon Yew Yin
3
4
Axcapital's investment blog
KAB - Executing its way to a record quarter. Could more Petronas contracts be coming?
6
save malaysia!
Visa-free travel to China extended for Malaysians to 30 days
7
8
#
Stock
Score
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
